Valproic Acid API from Japan Manufacturers & Suppliers

Valproic Acid is used as an anticonvulsant and mood stabilizer for treating complex partial seizures, absence seizures, and mixed seizure types that include absence seizures. It is also indicated for acute management of mania in bipolar disorder and for prophylaxis of migraine headaches.

Valproic Acid belongs to the following therapeutic categories: Acids, Acyclic, Anti-epileptic Agent, Anticonvulsants, Antimanic Agents, Antineoplastic Agents. This positioning helps teams compare alternative APIs, anticipate pharmacology expectations, and align early research priorities.

The primary indications for Valproic Acid: Indicated** for:[Label], Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures, Adjunctive therapy in the management of multiple seizure types that include absence seizures, Prophylaxis of migraine headaches. These use cases frame the target patient populations and help prioritize formulation and safety evaluations.

The exact mechanisms by which valproate exerts it's effects on epilepsy, migraine headaches, and bipolar disorder are unknown however several pathways exist which may contribute to the drug's action. Valproate is known to inhibit succinic semialdehyde dehydrogenase.This inhibition results in an increase in succinic semialdehyde which acts as an inhibitor of GABA transaminase ultimately reducing GABA metabolism and increasing GABAergic neurotransmission. As GABA is an inhibitory neurotransmitter, this increase results in increased inhibitory activity.A possible secondary contributor to cortical inhibition is a direct suppression of voltage gated sodium channel activity and indirect suppression through effects on GABA. It has also been suggested that valproate impacts the extracellular signal-related kinase pathway (ERK).These effects appear to be dependent on mitogen-activated protein kinase (MEK) and result in the phosphorylation of ERK1/2. This activation increases expression of several downstream targets including ELK-1 with subsequent increases in c-fos, growth cone-associated protein-43 which contributes to neural plasticity, B-cell lymphoma/leukaemia-2 which is an anti-apoptotic protein, and brain-derived neurotrophic factor (BDNF) which is also involved in neural plasticity and growth. Increased neurogenesis and neurite growth due to valproate are attributed to the effects of this pathway. An additional downstream effect of increased BDNF expression appears to be an increase in GABA_A receptors which contribute further to increased GABAergic activity. Valproate exerts a non-competitive indirect inhibitory effect on myo-inosital-1-phophate synthetase.This results in reduced de novo synthesis of inositol monophosphatase and subsequent inositol depletion. It is unknown how this contributed to valproate's effects on bipolar disorder but [lithium] is known to exert a similar inositol-depleting effect.Valproate exposure also appears to produce down-regulation of protein kinase C proteins (PKC)-α and -ε which are potentially related to bipolar disorder as PKC is unregulated in the frontal cortex of bipolar patients. This is further supported by a similar reduction in PKC with lithium.The inhibition of the PKC pathway may also be a contributor to migraine prophylaxis.Myristoylated alanine-rich C kinase substrate, a PKC substrate, is also downregulated by valproate and may contribute to changes in synaptic remodeling through effects on the cytoskeleton. Valproate also appears to impact fatty acid metabolism.Less incorporation of fatty acid substrates in sterols and glycerolipids is thought to impact membrane fluidity and result in increased action potential threshold potentially contributing to valproate's antiepileptic action.Valproate has been found to be a non-competitive direct inhibitor of brain microsomal long-chain fatty acyl-CoA synthetase.Inhibition of this enzyme decreases available arichidonyl-CoA, a substrate in the production of inflammatory prostaglandins. It is thought that this may be a mechanism behind valproate's efficacy in migraine prophylaxis as migraines are routinely treated with non-steroidal anti-inflammatory drugs which also inhibit prostaglandin production. Finally, valproate acts as a direct histone deactylase (HDAC) inhibitor.Hyperacetylation of lysine residues on histones promoted DNA relaxation and allows for increased gene transcription. The scope of valproate's genomic effects is wide with 461 genes being up or down-regulated.The relation of these genomic effects to therapeutic value is not fully characterized however H3 and H4 hyperacetylation correlates with improvement of symptoms in bipolar patients.Histone hyperacetylation at the BDNF gene, increasing BDNF expression, post-seizure is known to occur and is thought to be a neuroprotective mechanism which valproate may strengthen or prolong.H3 hyperacetylation is associated with a reduction in glyceraldehyde-3-phosphate dehydrogenase, a pro-apoptotic enzyme, contributing further to valproate's neuroprotective effects.

Valproic Acid has moderate acute toxicity, with reported oral LD50 values of 1098 mg/kg in mice and 670 mg/kg in rats. Clinically, it is associated with hepatotoxicity, teratogenicity, and narrow‑therapeutic‑index behavior requiring serum level monitoring. Overdose can cause central nervous system depression, cardiac conduction abnormalities, and electrolyte imbalance. Its broad metabolic and genomic effects also contribute to drug–drug interaction risk and require careful clinical oversight.

Valproic Acid requires attention to its moderate water solubility and fatty‑acid properties, which may necessitate solubilizers or buffering in liquid oral products to maintain stability. Oral formulations commonly use delayed‑ or extended‑release systems to reduce gastric irritation and manage absorption characteristics. Intravenous products typically employ the sodium salt and must be prepared within a controlled pH range to maintain solubility and avoid precipitation during dilution and administration. Proper handling ensures consistent delivery across oral and IV formulations.

Valproic Acid is classified as a small molecule. That classification shapes process design, impurity profiling, and analytical control strategies.

Oral Valproic Acid shows moderate water solubility and fatty‑acid characteristics, so liquid preparations may require solubilizers or buffering to maintain stability. Solid oral products often use delayed‑ or extended‑release matrices that help control absorption and reduce gastric irritation. These matrix systems also support chemical stability by limiting exposure to low gastric pH.